Sanjivani Paranteral Ltd

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a fair to a very attractive rating. Despite recent share price declines, the company’s improved price-to-earnings and price-to-book ratios relative to peers and historical averages suggest a compelling entry point for discerning investors.

Sanjivani Paranteral Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 21 May 2026. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the stock’s current position as of 02 June 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Sanjivani Paranteral Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its quality, valuation, financial trends, and technical indicators. The downgrade reflects deteriorating fundamentals, a shift in valuation metrics, and weakening financial performance, signalling caution for investors in this micro-cap pharmaceutical player.

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a very attractive to a fair valuation grade. This change comes amid significant price fluctuations and a deteriorating market sentiment, reflected in its recent downgrade to a Strong Sell rating by MarketsMOJO. Investors are now reassessing the stock’s price attractiveness in comparison to its historical averages and peer group benchmarks.

A sharp decline has pushed Sanjivani Paranteral Ltd to a fresh 52-week low of Rs 126 on 21 May 2026, marking a 41.44% drop over the past year, significantly underperforming the Sensex's 7.27% decline during the same period.

A sustained decline has pushed Sanjivani Paranteral Ltd to a fresh 52-week low of Rs 126 on 21 May 2026, marking a 41.44% drop over the past year, significantly underperforming the Sensex’s 7.27% decline in the same period.

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently seen its quality grade downgraded from good to average by MarketsMOJO on 12 May 2026. This shift reflects a nuanced change in the company’s business fundamentals, including key metrics such as return on equity (ROE), return on capital employed (ROCE), debt levels, and growth consistency. This article delves into the specifics behind this downgrade, analysing what has improved and what has deteriorated in the company’s financial health and operational performance.

Sanjivani Paranteral Ltd., a WHO-GMP certified pharmaceutical manufacturer specialising in injectables and oral solids, reported deeply disappointing results for Q4 FY26, with net profit plummeting 74.89% year-on-year to ₹0.55 crores from ₹2.19 crores in the corresponding quarter last year. The sequential decline was even more alarming, with profits collapsing 80.22% from ₹2.78 crores in Q3 FY26. The micro-cap company, valued at ₹161.00 crores, saw its shares tumble 12.64% following the results announcement, reflecting investor concern over the sharp deterioration in profitability despite a respectable 29.60% revenue growth for the full year FY25.

For the second consecutive session, Sanjivani Paranteral Ltd has seen its share price decline sharply, hitting a fresh 52-week low of Rs 128.2 on 15 Jun 2026. This drop comes amid a broader market rally, underscoring the stock's distinct weakness within the Pharmaceuticals & Biotechnology sector.

Sanjivani Paranteral Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by an improved valuation profile, robust financial trends, and solid quality metrics. Despite recent share price weakness, the company’s fundamentals and operational efficiency have strengthened, prompting a reassessment of its market stance.

Sanjivani Paranteral Ltd has witnessed a notable shift in its valuation parameters, moving from a previously fair valuation to an attractive one, as reflected in its updated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change, coupled with a recent upgrade in its Mojo Grade from Sell to Hold, suggests a recalibration of market sentiment towards the pharmaceuticals and biotechnology micro-cap, despite recent price volatility and underperformance relative to the Sensex.

Sanjivani Paranteral Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Apr 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 02 May 2026, providing investors with the latest perspective on the company’s position in the market.

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 20 Apr 2026. This decision follows a comprehensive reassessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals. Despite some positive long-term growth indicators, the stock’s recent performance and technical signals have raised concerns among analysts, prompting a cautious stance.

Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 15 Apr 2026. This shift reflects nuanced changes across four key parameters: quality, valuation, financial trend, and technicals. Despite a challenging year marked by underperformance relative to the broader market, the company’s improving fundamentals and technical indicators have prompted a reassessment of its outlook.